Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers
- PMID: 17222788
- PMCID: PMC2952447
- DOI: 10.1016/j.ccr.2006.12.008
Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers
Abstract
Clinical assessment of the response to antiangiogenic therapy has been cumbersome. A study in this issue of Cancer Cell demonstrates that a combination of magnetic resonance imaging (MRI) for quantification of normalized vessels with measurements of circulating levels of proangiogenic factors, including FGF2, SDF1, and viable circulating endothelial cells, provides an effective means to evaluate the response of recurrent glioblastoma to a prototypical pan-VEGF receptor tyrosine kinase inhibitor, AZD2171.
Figures

Comment on
-
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.Cancer Cell. 2007 Jan;11(1):83-95. doi: 10.1016/j.ccr.2006.11.021. Cancer Cell. 2007. PMID: 17222792 Free PMC article. Clinical Trial.
References
-
- Cha S. Magn Reson Imaging Clin N Am. 2003;11:403–413. - PubMed
-
- Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. Magn Reson Med. 1998;40:793–799. - PubMed
-
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. N Engl J Med. 2005;352:997–1003. - PubMed
-
- Jain RK. Science. 2005;307:58–62. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical